Cardiovascular

Patients with High Restenosis Risk Benefit More from Drug Eluting Stents

Raul Moreno
Raul Moreno

REFERENCE: Abstract 3103, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
RAUL MORENO, University Hospital La Paz, Madrid
Results from a large meta analysis suggest that drug eluting stents have a greater benefit when the risk of restenosis increases. This could affect the “off label” use of these stents. Raul Moreno, of the University Hospital La Paz, Madrid, discussed his findings with Derek Thorne.

Similar Interviews

  • Drug-eluting Stents: Cost-Benefit Targeting?
  • Matthias Pfisterer Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm

  • Drug-eluting Stents: No Benefit in Vein Grafts
  • Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis

  • Audio Journal of Cardiovascular Medicine: Sirolimus-Eluting Better Than Uncoated Stents for Primary Angioplasty
  • CHRISTIAN SPAULDING, Cochin Hospital, Paris REFERENCE: N Engl J Med 2006;355:1093, 1105,1169 Two leading articles in the same edition of the New

    Post a comment

    Subscribe to Audio Medica Podcast